In the recently published study by Zhong et al, “A Randomized Controlled Trial on the Effects of Low-Dose Extracorporeal Shockwave Therapy in Patients With Knee Osteoarthritis,” the researchers studied low-dose extracorporeal shockwave therapy (ESWT) treatment in patients with knee osteoarthritis. They stated that ESWT was superior to placebo in both pain and functional improvement, as well as in terms of negative effects on the articular cartilage.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Archives of Physical Medicine and Rehabilitation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database.Br Med Bull. 2015; 116: 115
- Application and efficacy of extracorporeal shockwave treatment for knee osteoarthritis: a systematic review and meta-analysis.Exp Ther Med. 2019; 18: 2843-2850
- Repetitive low-energy shock wave treatment for chronic lateral epicondylitis in tennis players.Am J Sports Med. 2004; 32: 734-743
- A systematic review of shockwave therapies in soft tissue conditions: focusing on the evidence.Br J Sports Med. 2014; 48: 1538-1542
Published online: May 14, 2020
© 2020 by the American Congress of Rehabilitation Medicine
ScienceDirectAccess this article on ScienceDirect
- Response to Letter Regarding “A Randomized Controlled Trial on the Effects of Low-Dose Extracorporeal Shockwave Therapy in Patients With Knee Osteoarthritis”Archives of Physical Medicine and RehabilitationVol. 101Issue 7
- PreviewWe would like to express our appreciation to the authors of the letter to the editor for their interest in our recent article.1 They argued that the control group in our study should be considered a very low dose extracorporeal shockwave therapy (ESWT) group rather than a placebo. We see their comments as an opportunity to provide more insight into designing a placebo in the ESWT study. The following is our explanation of the control group as a placebo group in our trial.